Viewing Study NCT07178795


Ignite Creation Date: 2025-12-24 @ 2:08 PM
Ignite Modification Date: 2025-12-24 @ 2:08 PM
Study NCT ID: NCT07178795
Status: RECRUITING
Last Update Posted: 2025-11-17
First Post: 2025-09-11
Is Possible Gene Therapy: False
Has Adverse Events: False

Brief Title: A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module